Company Description

Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States.

The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata.

Forte Biosciences, Inc. is headquartered in Dallas, Texas.

Forte Biosciences, Inc.

Country	United States
Industry	Biotechnology
Sector	Healthcare
Employees	9
CEO	Dr. Paul A. Wagner Ph.D.

Contact Details

Address: 3060 Pegasus Park Drive, Building 6 Dallas, Texas 75247 United States
Phone	(310) 618-6994
Website	fortebiorx.com

Stock Details

Ticker Symbol	FBRX
Exchange	NASDAQ
Fiscal Year	January - December
Reporting Currency	USD
CIK Code	0001419041
CUSIP Number	34962G109
ISIN Number	US34962G1094
Employer ID	26-1243872
SIC Code	2834

Key Executives

Name	Position
Dr. Paul A. Wagner Ph.D.	Chief Executive Officer, President and Chairman
Antony A. Riley CPA	Chief Financial Officer
Christopher Roenfeldt	Chief Operating Officer
Steven Ruhl	Chief Technical Officer

Latest SEC Filings

Date	Type	Title
Apr 12, 2024	S-8	Securities to be offered to employees in employee benefit plans
Mar 18, 2024	10-K	Annual Report
Mar 18, 2024	8-K	Current Report
Feb 16, 2024	8-K/A	[Amend] Current report
Feb 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024	SC 13G	Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024	SC 13G/A	[Amend] Statement of acquisition of beneficial ownership by individuals
Jan 11, 2024	SC 13D/A	[Amend] General statement of acquisition of beneficial ownership
Jan 9, 2024	SC 13D/A	[Amend] General statement of acquisition of beneficial ownership

View All SEC Filings